Pregnancy Weight Gain Excess Linked to Maternal Health Risks

GLP-1 Receptor Agonist Discontinuation and Weight Gain

Research following pregnancies found that discontinuing GLP-1 receptor agonist therapy before conception or during early pregnancy was associated with greater gestational weight gain. Exposed pregnancies had a mean weight gain of 13.7 kilograms, while matched unexposed pregnancies had a mean of 10.5 kilograms, a difference of 3.3 kilograms. This weight gain pattern was observed across a cohort primarily of women with obesity.

Increased Pregnancy Complications

The same study reported higher rates of adverse pregnancy outcomes among GLP-1 RA-exposed pregnancies. Exposed individuals faced a 65 percent rate of excess gestational weight gain compared to 49 percent in unexposed pregnancies. Additional risks included preterm delivery at 17 percent versus 13 percent, gestational diabetes at 20 percent versus 15 percent, and hypertensive disorders at 46 percent versus 36 percent.

Birth Weight and Long-Term Considerations

Exposed pregnancies also showed higher mean birth weight percentiles, with 58.4 percent compared to 54.8 percent in unexposed groups. Researchers noted that while these findings highlight important clinical considerations, limitations exist regarding generalizability due to the study population’s demographics. Further research is needed to define clinical approaches to mitigate excess gestational weight gain in individuals using GLP-1 RAs before pregnancy.